Bristol Myers Squibb announced a new analysis of data from the Phase 3 EXPLORER-HCM study evaluating mavacamten, an investigational, first-in-class cardiac myosin inhibitor, in patients with obstructive hypertrophic cardiomyopathy (oHCM), which was presented at the American College of Cardiology’s 70th Annual Scientific Session with simultaneous publication in The Lancet.
Shares of MyoKardia shot up more than 64 percent in trading following an announcement that the company’s lead drug mavacamten hit the mark in a Phase III study of patients with symptomatic, obstructive hypertrophic cardiomyopathy (HCM).
